Alpine Immune Sciences Announces Participation in March Investor Conferences

On March 1, 2022 Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, reported that members of its management team will participate at the following investor conferences in March 2022 (Press release, Alpine Immune Sciences, MAR 1, 2022, View Source [SID1234609250]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen’s 42nd Annual Health Care Conference
Date: Monday, March 7, 2022
Time: 2:50 p.m. ET/11:50 a.m. PT
Event: Fireside Chat

Oppenheimer 32nd Annual Healthcare Conference
Date: Thursday, March 17, 2022
Time: 2:40 p.m. ET/11:40 a.m. PT
Event: Fireside Chat

Webcasts of the Cowen and Oppenheimer fireside chats will be available online in the investor relations section of the company’s website at View Source A replay of the fireside chats will be available on the company website for 90 days following the webcast.

Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference

On March 1, 2022 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, reported that the company will participate in the Cowen 42nd Annual Health Care Conference(Press release, Revolution Medicines, MAR 1, 2022, View Source [SID1234609276]). Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the company’s participation are as follows:

Cowen 42nd Annual Health Care Conference
Conference Date: March 7-9, 2022
Fireside Chat Time/Date: 11:10 a.m. Pacific on Monday, March 7, 2022
Format: Virtual conference; webcast available
To access the live webcast of the fireside chat, please visit the "Events & Presentations" page of Revolution Medicines’ website at View Source Additionally, a replay of the webcast will be available on the "Events & Presentations" page of the Revolution Medicines website for at least 14 days following the conference.

Janux Therapeutics to Present at Upcoming March Investor Conferences

On March 1, 2022 Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, reported that Janux management will participate in three upcoming investor conferences (Press release, Janux Therapeutics, MAR 1, 2022, View Source [SID1234609292]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen’s 42nd Annual Health Care Conference
Forum: Panel titled "Novel IO"
Location: Virtual
Date: Monday, March 7
Time: 10:30 a.m. – 11:30 a.m. ET

Barclays Global Healthcare Conference
Forum: Corporate Presentation
Location: Miami, Florida
Date: Wednesday, March 16
Time: 2:35 p.m. – 3:00 p.m. ET

Oppenheimer’s 32nd Annual Healthcare Conference
Forum: Corporate PresentationLocation: Virtual
Date: Thursday, March 17
Time: 8:40 a.m. – 9:10 a.m. ET

All presentations and subsequent archived replays may be accessed via the Investors & Media section of Janux’s website. An archived replay of the webcasts will be available on the website for approximately 90 days following the presentation.

Cardiff Oncology to Participate in Cowen’s 42nd Annual Healthcare Conference

On March 1, 2022 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, reported that company management will participate in a panel discussion and one-on-one investor meetings at Cowen’s 42nd Annual Healthcare Conference taking place virtually March 7-9, 2022 (Press release, Cardiff Oncology, MAR 1, 2022, View Source [SID1234609310]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the panel can be found below.

A replay of the panel discussion will be available by visiting the "Events" section of the Cardiff Oncology website and will be archived for 30 days after the conference’s conclusion.

Signify Health completes acquisition of Caravan Health

On March 1, 2022 Signify Health, Inc. (NYSE: SGFY), a leading value-based healthcare platform that leverages advanced analytics, technology and nationwide healthcare provider networks, reported it has completed the acquisition of Caravan Health, a leader in enabling accountable care organizations (ACOs) to excel in population health management and value-based payment programs (Press release, Signify Health, MAR 1, 2022, View Source [SID1234609339]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The combination creates one of the largest national networks of providers engaged in value-based payment models. Signify Health will now enable a broader range of value-based and shared savings models from advanced primary care to specialty care bundles to total cost of care programs. The Company also will now be well-positioned to serve community hospitals, physician practices and clinics – entities who have been slower to adopt episodes of care and bundled payments due to lack of infrastructure to do so. With the completion of this acquisition, Signify Health now will support approximately $10 billion in total medical spend under management.

"Giving providers a multi-payor solution ensures that what they do for one patient can be done for all others, irrespective of coverage or individual characteristics," said Kyle Armbrester, CEO of Signify Health. "With the combined capabilities of Signify and Caravan, we will be able to give providers what they need – one platform to manage better health outcomes for all of their patients, from a simple condition or procedure to a complex combination and across multiple payors. I’m looking forward to working with our expanded team to unlock these opportunities and help our clients bring their value-based care strategies to scale – and improve health outcomes across a range of payment models."

Pursuant to the agreement previously announced on February 10, 2022, the transaction is valued at an initial purchase price of $250 million, consisting of $190 million in cash and $60 million in Signify Health common stock. The transaction also includes contingent additional payments of up to $50 million in cash based on the future performance of Caravan Health, which was backed by VSS Capital Partners. Signify Health intends to provide guidance for the combined company when it reports its financial results for the fourth quarter and full year 2021 results on March 2, 2022.